Back to results
US 11,766,413 B2Granted
Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
AssigneeNacuity Pharmaceuticals, Inc.
InventorG. Michael Wall
Life of this patent
Estimating the term…
Abstract
The present invention includes a method for the treatment of age-related macular degeneration, glaucoma, or diabetic retinopathy in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to treat or reduce the symptoms of the age-related macular degeneration, glaucoma, or diabetic retinopathy.
Claims17
A method for treatment of age-related macular degeneration, glaucoma, or diabetic retinopathy in a human subject that comprises:
- identifying a human patient in need of treatment for age-related macular degeneration, glaucoma, or diabetic retinopathy;
- and
- administering to the human patient a therapeutically effective amount of (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA), wherein a concentration of the diNACA in the retina is greater than a plasma concentration after 4 hours.
Dependencies are inferred from the claim text.